Criteria
GINA criteria for the severity of asthma exacerbations[7]
For children 5 years or younger
Mild or moderate:
Breathless, agitated
Pulse rate ≤180 beats per minute (bpm) (0-3 years) or ≤150 bpm (4-5 years)
Oxygen saturation (on air) ≥92%
Severe or life-threatening:
Unable to speak or drink
Central cyanosis
Confusion or drowsiness
Respiratory rate >40/minute
Oxygen saturation (on air) <92%
Silent chest on auscultation
Pulse rate >180 bpm (0-3 years) or >150 bpm (4-5 years)
For children 6-11 years
Mild or moderate:
Talks in phrases, prefers sitting to lying, not agitated
Respiratory rate increased
Accessory muscles not used
Pulse rate 100-120 bpm
Oxygen saturation (on air) 90% to 95%
PEF >50% predicted or best
Severe:
Talks in words, sits hunched forwards, agitated
Respiratory rate >30/minute
Accessory muscles in use
Pulse rate >120 bpm
Oxygen saturation (on air) <90%
PEF ≤50% predicted or best
Life-threatening:
Drowsy, confused, or with silent chest
NAEPP/NHLBI criteria for the severity of asthma exacerbations[50]
These criteria cover all ages (including adults).
Mild:
Dyspnoea only with activity; patient talks in sentences
Increased respiratory rate; no increase in heart rate
Usually no accessory muscle use or suprasternal retractions
Moderate wheeze (often only end expiratory)
Absent pulsus paradoxus (<10 mmHg)
Oxygen saturation on air >95%
Peak expiratory flow (PEF) (or forced expiratory volume in the first second of expiration [FEV₁]) 70% or more of predicted or percentage of personal best.
Moderate:
Dyspnoea interferes with or limits usual activity; patient talks in phrases
Increased respiratory rate and heart rate
Often has accessory muscle use and suprasternal retractions
Loud wheeze (throughout exhalation)
Pulsus paradoxus may be present (10-25 mmHg)
Oxygen saturation (on air) 90% to 95%
PEF (or FEV₁) 40% to 69% predicted or percentage of personal best.
Severe and life-threatening:
Dyspnoea at rest; cessation of feeding in infants; agitation or drowsiness; speaking in single words or inability to speak
Increased respiratory rate and heart rate
Accessory muscle use and suprasternal retractions; may have thoraco-abdominal movement
Usually loud wheeze (throughout inhalation and exhalation), but wheeze may be absent (silent chest)
Pulsus paradoxus often present in severe exacerbations (20-40 mmHg in a child); in a severe exacerbation, the absence of pulsus paradoxus suggests respiratory muscle fatigue and imminent respiratory arrest
Oxygen saturation (on air) <90%
Cyanosis may be present
Partial pressure of oxygen (PaO₂) (on air) <60 mmHg; partial pressure of carbon dioxide (PaCO₂) ≥42 mmHg
PEF (or FEV₁) 25% to 39% (severe) or <25% (life-threatening) predicted or percentage of personal best.
BTS/NICE/SIGN criteria for the severity of asthma exacerbations[57]
If a patient has signs and symptoms across categories, always treat according to their most severe features.
For children aged <2 years
Moderate asthma:
Oxygen saturation measured by pulse oximetry (SpO₂) (on air) ≥92%
Audible wheeze and using accessory muscles
Still feeding
No clinical features of acute severe asthma
Acute severe asthma:
SpO₂ (on air) <92%
Cyanosis
Marked respiratory distress
Too breathless to feed
For children aged 2-5 years:
Moderate asthma:
Oxygen saturation measured by pulse oximetry (SpO₂) (on air) ≥92%
No clinical features of acute severe asthma
Acute severe asthma:
SpO₂ (on air) <92%
Too breathless to talk or eat
Heart rate >140/minute
Respiratory rate >40/minute
Use of accessory neck muscles
Life-threatening asthma:
SpO₂ (on air) <92% plus any of:
Silent chest
Poor respiratory effort
Agitation
Confusion
Cyanosis
For children aged over 5 years
Moderate asthma:
SpO₂ (on air) ≥92%
PEF ≥50% best or predicted
No clinical features of severe asthma
Acute severe asthma:
SpO₂ (on air) <92%
PEF 33% to 50% best or predicted
Heart rate >125/minute
Respiratory rate >30/minute
Use of accessory neck muscles
Life-threatening asthma:
SpO₂ (on air) <92% plus any of:
PEF <33% best or predicted
Silent chest
Poor respiratory effort
Altered consciousness
Cyanosis
Use of this content is subject to our disclaimer